Shanghai Kehua Bio-Engineering Co Ltd

Capital Structure and Liquidity Shanghai Kehua Bio-Engineering has a debt-to-equity ratio of 0.28, indicating a relatively conservative capital structure. However, the company reported negative free cash flow of -800.73 million CNY and negative operating cash flow of 22.44 million CNY, suggesting liquidity constraints. The current ratio of 1.78 implies the company has sufficient short-term assets to cover its short-term liabilities, but the negative net cash position after subtracting total debt raises concerns about its ability to meet long-term obligations. ### Profitability and Returns The company is currently unprofitable, with a net loss of 732.14 million CNY and an operating loss of 811.07 million CNY. Return on equity (ROE) is -27.75%, and return on assets (ROA) is -15.77%, both significantly below industry norms for a biotechnology firm. These metrics suggest poor capital efficiency and operational performance relative to its peers. ### Segments and Geographic Exposure The company operates primarily in the domestic Chinese market, with no disclosed international revenue segments. Its business is concentrated in the production and sale of diagnostic reagents and instruments, with no material diversification across product lines or geographic regions. ### Growth Trajectory Despite a reported revenue of 1.64 billion CNY, the company's operating and net losses indicate a lack of profitability. Analysts have recorded a last actual revenue of 4.13 billion CNY, but this appears to be a discrepancy or a misalignment in reporting periods. The company's capital expenditures of -139.29 million CNY suggest ongoing investment in infrastructure, but the negative free cash flow indicates that these investments are not yet generating returns. ### Risk Factors The company faces medium liquidity risk due to its negative free cash flow and negative net cash position after debt. Dilution risk is currently low, as there is no indication of significant share issuance or dilution pressure in the near term. However, the company's unprofitability and negative operating cash flow could lead to future capital-raising activities that may dilute existing shareholders. ### Recent Events Recent financial filings show a significant decline in profitability, with a net loss of 732.14 million CNY and an operating loss of 811.07 million CNY. The company has not disclosed any major strategic changes or new product launches in recent transcripts or filings, suggesting a period of operational stagnation or decline.